Quinine and its use to generate innate immune response
AssigneeThe Trustees of the University of Pennsylvania
InventorsNoam Cohen, Robert J. Lee, Susan R. Weiss, Joel N. Maslow, Christine C. Roberts, Sara Cherry, Michael Kohanski, Nithin D. Adappa, James N. Palmer, Li Hui Tan
Life of this patent
Estimating the term…
Abstract
The invention provides methods and compositions for assaying infectivity of viruses and potential treatments of such viruses in the upper respiratory tract using an air-liquid interface model with nasal epithelium cells; and treatment of viral infections of the upper respiratory tract by treating with bitter taste receptor agonists that stimulate NO production and/or antimicrobial protein production.
Claims13
A method of treating a viral infection in a subject having an upper respiratory infection, comprising:
- dispersing as particulate a formulation of a bitter taste receptor agonist,
- wherein the bitter taste receptor agonist is selected from the group consisting of:
- denatonium, phenylthiocarbamide (PTC), a homoserine lactone, sodium thiocyanate (NaSCN), 6-n-propylthio uracil (PROP or PTU), parthenolide, amarogentin, antidesma, antidesma extract, colchicine, dapsone, salicin, quinine, and quinine salts;
- applying the dispersed formulation onto the mucosal surface of an upper respiratory cavity of the subject;
- and
- generating nitric oxide (NO) production or stimulating antimicrobial peptide production, or both, through the stimulation of bitter taste receptors;
- wherein the viral infection is an infection resulting from a virus selected from the group consisting of:
- SARS;
- SARS-CoV-2;
- MERS-CoV;
- SARS-CoV;
- adenovirus;
- human metapneumovirus;
- respiratory syncytial virus;
- and non-pathogenic coronaviruses.
A method of treating a viral infection in a subject having an upper respiratory infection, comprising:
- dispersing as particulate a formulation of a bitter taste receptor agonist at a concentration of between 0.5 mg/ml and 1 mg/ml;
- applying the dispersed formulation onto the mucosal surface of an upper respiratory cavity of the subject;
- and
- generating nitric oxide (NO) production or stimulating antimicrobial peptide production, or both, through the stimulation of bitter taste receptors;
- wherein the viral infection is an infection resulting from a virus selected from the group consisting of:
- SARS;
- SARS-CoV-2;
- MERS-CoV;
- SARS-CoV;
- adenovirus;
- human metapneumovirus;
- respiratory syncytial virus;
- and non-pathogenic coronaviruses.
Dependencies are inferred from the claim text.